Beresford I J, Birch P J, Hagan R M, Ireland S J
Department of Neuropharmacology, Glaxo Group Research Ltd., Ware, Hertfordshire.
Br J Pharmacol. 1991 Oct;104(2):292-3. doi: 10.1111/j.1476-5381.1991.tb12423.x.
The affinity of the non-peptide antagonist CP-96,345 for tachykinin NK1 receptors has been estimated in a range of species by use of both radioligand binding and functional assays. CP-96,345 was 30-120 fold less active at NK1 receptors in rat and mouse than in the other species examined, including man. These results demonstrate the existence of species variations in NK1 receptors.
通过放射性配体结合和功能测定,已在一系列物种中估计了非肽拮抗剂CP - 96,345对速激肽NK1受体的亲和力。与包括人类在内的其他受试物种相比,CP - 96,345在大鼠和小鼠的NK1受体上的活性要低30至120倍。这些结果证明了NK1受体存在物种差异。